| SMMT Stock | | | USD 21.10 0.21 1.01% |
Summit Therapeutics financial indicator trend analysis is much more than just breaking down Summit Therapeutics PLC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Summit Therapeutics PLC is a good investment. Please check the relationship between Summit Therapeutics Other Operating Expenses and its Gross Profit accounts. Check out
World Market Map to better understand how to build diversified portfolios, which includes a position in Summit Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in population.
Other Operating Expenses vs Gross Profit
Other Operating Expenses vs Gross Profit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Summit Therapeutics PLC Other Operating Expenses account and
Gross Profit. At this time, the significance of the direction appears to have no relationship.
The correlation between Summit Therapeutics' Other Operating Expenses and Gross Profit is 0.0. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Gross Profit in the same time period over historical financial statements of Summit Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Summit Therapeutics' Other Operating Expenses and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Summit Therapeutics PLC are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Other Operating Expenses i.e., Summit Therapeutics' Other Operating Expenses and Gross Profit go up and down completely randomly.
Correlation Coefficient | 0.0 |
| Relationship Direction | Flat |
| Relationship Strength | Insignificant |
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Summit Therapeutics PLC. It is also known as Summit Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Gross Profit
Gross profit is a required income statement account that reflects total revenue of Summit Therapeutics PLC minus its cost of goods sold. It is profit before Summit Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.
Most indicators from Summit Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Summit Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
World Market Map to better understand how to build diversified portfolios, which includes a position in Summit Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in population.
At this time, Summit Therapeutics'
Selling General Administrative is comparatively stable compared to the past year.
Sales General And Administrative To Revenue is likely to gain to 35.83 in 2024, whereas
Enterprise Value Over EBITDA is likely to drop
(19.78) in 2024.
Summit Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Summit Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Summit Therapeutics fundamental ratios Accounts
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to
measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.